Critically ill patients who are subjected to high stress or with severe injury can rapidly break down their body protein and energy stores. Unless adequate nutrition is provided, malnutrition and protein wasting may occur, which can negatively affect patient outcome. Enteral nutrition (EN) is the mainstay of nutrition support therapy in patients with a functional gastrointestinal (GI) tract who cannot take adequate oral nutrition. EN in critically ill patients provides the benefits of maintaining gut functionality, integrity, and immunity as well as decreasing infectious complications. However, the ability to provide timely and adequate EN to critically ill patients is often hindered by GI motility disorders and complications associated with EN. This paper reviews the GI complications and intolerances associated with EN in critically ill patients and provides recommendations for their prevention and treatment. It also addresses the role of commonly used medications in the intensive care unit and their impact on GI motility and EN delivery.
BioloGGrimbleGPreiserJC; European Society of Intensive Care Medicine Working Group on Nutrition and Metabolism. Position paper of the ESICM Working Group on Nutrition and Metabolism. Metabolic basis of nutrition in intensive care unit patients: Ten critical questions. Intensive Care Med. 2002;28:1512-1520.
2.
DaleyBJBistrianBR. Nutritional assessment. In: ZalogaGP, ed. Nutrition in Critical Care. St. Louis, MO: Mosby-Year Book; 1994:9-33.
3.
WolfeRR. Carbohydrate metabolism in critically ill patients: implications for nutritional support. Crit Care Clin. 1987;3:11-24.
4.
SchmidtHMartindaleR. The gastrointestinal tract in critical illness. Curr Opin Clin Nutr Metab Care. 2001;4:547-551.
5.
MarikPEZalogaGP. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med. 2001;29:2264-2270.
6.
LewisSJEggerMSylvesterPAThomasS. Early enteral feeding versus “nil by mouth” after gastrointestinal surgery: systematic review and meta-analysis of controlled trials. BMJ. 2001;323:773-776.
7.
HeylandDKDhaliwalRDroverJWGramlichLDodekP; Canadian Critical Care Clinical Practice Guidelines Committee. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr. 2003;27:355-373.
8.
McClaveSAMartindaleRGVanekVW; A.S.P.E.N. Board of Directors; American College of Critical Care Medicine; Society of Critical Care Medicine. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2009;33:277-316.
9.
McClaveSASextonLKSpainDA. Enteral tube feeding in the intensive care unit: factors impeding adequate delivery. Crit Care Med. 1999;27:1252-1256.
10.
MallampalliAMcClaveSASniderHL. Defining tolerance to enteral feeding in the intensive care unit. Clin Nutr. 2000;19:213-215.
11.
MethenyNAClouseREChangYHStewartBJOliverDAKollefMH. Tracheobronchial aspiration of gastric contents in critically ill tube-fed patients: frequency, outcomes, and risk factors. Crit Care Med. 2006;34:1007-1015.
12.
DeaneAChapmanMJFraserRJBryantLKBurgstadCNguyenNQ. Mechanisms underlying feed intolerance in the critically ill: implications for treatment. World J Gastroenterol. 2007;13:3909-3917.
13.
BankheadRBoullataJBrantleyS; A.S.P.E.N. Board of Directors. Enteral nutrition practice recommendations. JPEN J Parenter Enteral Nutr. 2009;33:122-167.
14.
AdamSBatsonS. A study of problems associated with the delivery of enteral feed in critically ill patients in five ICUs in the UK. Intensive Care Med. 1997;23:261-266.
15.
HeylandDCookDJWinderBBrylowskiLVan deMarkHGuyattG. Enteral nutrition in the critically ill patient: a prospective survey. Crit Care Med. 1995;23:1055-1060.
16.
MentecHDupontHBocchettiMCaniPPoncheFBleichnerG. Upper digestive intolerance during enteral nutrition in critically ill patients: frequency, risk factors, and complications. Crit Care Med. 2001;29:1955-1961.
17.
MontejoJC. Enteral nutrition-related gastrointestinal complications in critically ill patients: a multicenter study. The Nutritional and Metabolic Working Group of the Spanish Society of Intensive Care Medicine and Coronary Units. Crit Care Med. 1999;27:1447-1453.
18.
ReintamAParmPKitusRKernHStarkopfJ. Gastrointestinal symptoms in intensive care patients. Acta Anaesthesiol Scand. 2009;53:318-324.
19.
ZalogaGP. Parenteral nutrition in adult inpatients with functioning gastrointestinal tracts: assessment of outcomes. Lancet. 2006;367:1101-1111.
20.
FrostPEdwardsNBihariD. Gastric emptying in the critically ill–the way forward?Intensive Care Med. 1997;23:243-245.
21.
MartinCMDoigGSHeylandDKMorrisonTSibbaldWJ; Southwestern Ontario Critical Care Research Network. Multicentre, cluster-randomized clinical trial of algorithms for critical-care enteral and parenteral therapy (ACCEPT). CMAJ. 2004;170:197-204.
22.
EngelJMMuhlingJJungerAMengesTKarcherBHempelmannG. Enteral nutrition practice in a surgical intensive care unit: what proportion of energy expenditure is delivered enterally?Clin Nutr. 2003;22:187-192.
23.
PetrosSEngelmannL. Enteral nutrition delivery and energy expenditure in medical intensive care patients. Clin Nutr. 2006;25:51-59.
24.
O’MearaDMireles-CabodevilaEFrameF. Evaluation of delivery of enteral nutrition in critically ill patients receiving mechanical ventilation. Am J Crit Care. 2008;17:53-61.
25.
ElpernEHStutzLPetersonS. Outcomes associated with enteral tube feedings in a medical intensive care unit. Am J Crit Care. 2004;13:221-227.
26.
O’Leary-KelleyCMPuntilloKABarrJ. Nutritional adequacy in patients receiving mechanical ventilation who are fed enterally. Am J Crit Care. 2005;14:222-231.
27.
VilletSChioleroRLBollmannMD. Negative impact of hypocaloric feeding and energy balance on clinical outcome in ICU patients. Clin Nutr. 2005;24:502-509.
28.
RubinsonLDietteGBSongXBrowerRGKrishnanJA. Low caloric intake is associated with nosocomial bloodstream infections in patients in the medical intensive care unit. Crit Care Med. 2004;32:350-357.
29.
HsuCWSunSFLinSL. Duodenal versus gastric feeding in medical intensive care unit patients: a prospective, randomized, clinical study. Crit Care Med. 2009;37:1866-1872.
30.
MarikPEZalogaGP. Gastric versus post-pyloric feeding: a systematic review. Crit Care. 2003;7:R46-R51.
31.
RohmKDBoldtJPiperSN. Motility disorders in the ICU: recent therapeutic options and clinical practice. Curr Opin Clin Nutr Metab Care. 2009;12:161-167.
32.
HerbertMKHolzerP. Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients; current status and future options. Clin Nutr. 2008;27:25-41.
33.
KellerJLayerP. Intestinal and anorectal motility and functional disorders. Best Pract Res Clin Gastroenterol. 2009;23:407-423.
34.
RitzMAFraserREdwardsN. Delayed gastric emptying in ventilated critically ill patients: measurement by 13 C-octanoic acid breath test. Crit Care Med. 2001;29:1744-1749.
35.
HeylandDKTougasGKingDCookDJ. Impaired gastric emptying in mechanically ventilated, critically ill patients. Intensive Care Med. 1996;22:1339-1344.
36.
KaoCHChangLaiSPChiengPUYenTC. Gastric emptying in head-injured patients. Am J Gastroenterol. 1998;93:1108-1112.
37.
OttLYoungBPhillipsR. Altered gastric emptying in the head-injured patient: Relationship to feeding intolerance. J Neurosurg. 1991;74:738-742.
38.
NortonJAOttLGMcClainC. Intolerance to enteral feeding in brain-injured patients. J Neurosurg. 1988;68:62-66.
LandzinskiJKiserTHFishDNWischmeyerPEMacLarenR. Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. JPEN J Parenter Enteral Nutr. 2008;32:45-50.
41.
NguyenNQChapmanMFraserRJBryantLKBurgstadCHollowayRH. Prokinetic therapy for feed intolerance in critical illness: one drug or two?Crit Care Med. 2007;35:2561-2567.
42.
MostafaSMBhandariSRitchieGGrattonNWenstoneR. Constipation and its implications in the critically ill patient. Br J Anaesth. 2003;91:815-819.
43.
PatanwalaAEAbarcaJHuckleberryYErstadBL. Pharmacologic management of constipation in the critically ill patient. Pharmacotherapy. 2006;26:896-902.
44.
AsaiT. Constipation: does it increase morbidity and mortality in critically ill patients?Crit Care Med. 2007;35:2861-2862.
45.
KehletHHolteK. Review of postoperative ileus. Am J Surg. 2001;182(5A suppl):3S-10S.
46.
FerrazAACowlesVECondonRE. Nonopioid analgesics shorten the duration of postoperative ileus. Am Surg. 1995;61:1079-1083.
47.
HolteKKehletH. Postoperative ileus: a preventable event. Br J Surg. 2000;87:1480-1493.
JakobSMMerasto-MinkkinenMTenhunenJJHeinoAAlhavaETakalaJ. Prevention of systemic hyperlactatemia during splanchnic ischemia. Shock. 2000;14:123-127.
50.
KreimeierU. Pathophysiology of fluid imbalance. Crit Care. 2000;4(suppl 2):S3-S7.
51.
MartikainenTJTenhunenJJGiovanniniIUusaroARuokonenE. Epinephrine induces tissue perfusion deficit in porcine endotoxin shock: evaluation by regional CO(2) content gradients and lactate-to-pyruvate ratios. Am J Physiol Gastrointest Liver Physiol. 2005;288:G586-G592.
52.
CreteurJDe BackerDSunQVincentJL. The hepatosplanchnic contribution to hyperlactatemia in endotoxic shock: effects of tissue ischemia. Shock. 2004;21:438-443.
53.
FruhwaldSHolzerPMetzlerH. Intestinal motility disturbances in intensive care patients pathogenesis and clinical impact. Intensive Care Med. 2007;33:36-44.
54.
SafaviMHonarmandA. Admission hypomagnesemia; impact on mortality or morbidity in critically ill patients. Middle East J Anesthesiol. 2007;19:645-660.
55.
StelfoxHTAhmedSBKhandwalaFZygunDShahporiRLauplandK. The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical-surgical intensive care units. Crit Care. 2008;12:R162.
56.
BealALScheltemaKEBeilmanGJDeuserWE. Hypokalemia following trauma. Shock. 2002;18:107-110.
57.
ChenJZDengAWXuJF. Electroenterogram manifestations and significance in hypokalemia. Di Yi Jun Yi Da Xue Xue Bao. 2005;25:7-9.
58.
DeSchepperHUCremoniniFParkMICamilleriM. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil. 2004;16:383-394.
59.
De LucaACouparIM. Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996;69:103-115.
60.
TittleMMcMillanSC. Pain and pain-related side effects in an ICU and on a surgical unit: nurses’ management. Am J Crit Care. 1994;3:25-30.
61.
BreitfeldCPetersJVockelT. Emetic effects of morphine and piritramide. Br J Anaesth. 2003;91:218-223.
62.
WirzSWittmannMSchenkM. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain. 2009;13:737-743.
63.
WeschulesDJBainKTReifsnyderJ. Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients. Pain Med. 2006;7:320-329.
64.
FruhwaldSScheidlSTollerW. Low potential of dobutamine and dopexamine to block intestinal peristalsis as compared with other catecholamines. Crit Care Med. 2000;28:2893-2897.
65.
DiveAForetFJamartJBulpaPInstalleE. Effect of dopamine on GI motility during critical illness. Intensive Care Med. 2000;26:901-907.
66.
LinHCNeevelCChenPSSuhGChenJH. Slowing of intestinal transit by fat or peptide YY depends on beta-adrenergic pathway. Am J Physiol Gastrointest Liver Physiol. 2003;285:G1310-G1316.
67.
TomitaRTanjohKFujisakiSIkedaTFukuzawaM. Regulation of the enteric nervous system in the colon of patients with slow transit constipation. Hepatogastroenterology. 2002;49:1540-1544.
68.
AndersonGNoorianARTaylorG. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson’s disease. Exp Neurol. 2007;207:4-12.
69.
SundaramU. Mechanism of intestinal absorption: effect of clonidine on rabbit ileal villus and crypt cells. J Clin Invest. 1995;95:2187-2194.
70.
MachT. The brain-gut axis in irritable bowel syndrome–clinical aspects. Med Sci Monit. 2004;10:RA125-RA131.
71.
BuchmanALFryerJWallinAAhnCWPolenskySZarembaK. Clonidine reduces diarrhea and sodium loss in patients with proximal jejunostomy: a controlled study. JPEN J Parenter Enteral Nutr. 2006;30:487-491.
72.
AsaiTMaplesonWWPowerI. Differential effects of clonidine and dexmedetomidine on gastric emptying and gastrointestinal transit in the rat. Br J Anaesth. 1997;78:301-307.
73.
HerbertMKRoth-GoldbrunnerSHolzerPRoewerN. Clonidine and dexmedetomidine potently inhibit peristalsis in the guinea pig ileum in vitro. Anesthesiology. 2002;97:1491-1499.
74.
MemişDDökmeciDKaramanlioğluBTuranATüreM. A comparison of the effect on gastric emptying of propofol or dexmedetomidine in critically ill patients: preliminary study. Eur J Anaesthesiol. 2006;23:700-704.
75.
ReadeMCO’SullivanKBatesSGoldsmithDAinslieWRBellomoR. Dexmedetomidine vs haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Crit Care. 2009;13:R75.
76.
WunschHKahnJMKramerAARubenfeldGD. Use of intravenous infusion sedation among mechanically ventilated patients in the United States. Crit Care Med. 2009;37:3031-3039.
77.
KatoJOgawaYKojimaWAokiKOgawaSIwasakiK. Cardiovascular reflex responses to temporal reduction in arterial pressure during dexmedetomidine infusion: a double-blind, randomized, and placebo-controlled study. Br J Anaesth. 2009;103:561-565.
78.
StewartRMParkPKHuntJP; National Institutes of Health/National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Less is more: improved outcomes in surgical patients with conservative fluid administration and central venous catheter monitoring. J Am Coll Surg. 2009;208:725-735.
79.
SakrYVincentJLReinhartK; Sepsis Occurrence in Acutely Ill Patients Investigators. High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest. 2005;128:3098-3108.
80.
RyanMP. Interrelationships of magnesium and potassium homeostasis. Miner Electrolyte Metab. 1993;19:290-295.
81.
HuangCLKuoE. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007;18:2649-2652.
82.
CaliRLMeadePGSwansonMSFreemanC. Effect of morphine and incision length on bowel function after colectomy. Dis Colon Rectum. 2000;43:163-168.
Culpepper-MorganJAInturrisiCEPortenoyRK. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther. 1992;52:90-95.
85.
SykesN. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10:135-144.
86.
LataschLZimmermannMEberhardtBJurnaI. Treament of morphine-induced constipation with oral naloxone. Anaesthesist. 1997;46:191-194.
87.
MixidesGLieblMGBloomK. Enteral administration of naloxone for treatment of opioid-associated intragastric feeding intolerance. Pharmacotherapy. 2004;24:291-294.
88.
MeissnerWDohrnBReinhartK. Enteral naloxone reduces gastric tube reflux and frequency of pneumonia in critical care patients during opioid analgesia. Crit Care Med. 2003;31:776-780.
89.
TofilNMBennerKWFaroSJWinklerMK. The use of enteral naloxone to treat opioid-induced constipation in a pediatric intensive care unit. Pediatr Crit Care Med. 2006;7:252-354.
90.
ThomasMCErstadBL. Safety of enteral naloxone and i.v. neostigmine when used to relieve constipation. Am J Health Syst Pharm. 2003;60:1264-1267.
91.
ArpinoPAThompsonBT. Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit. J Clin Pharm Ther. 2009;34:171-175.
92.
SimpkinJNSmulkowskiMDixonRTuttleR. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J Pharmacol Exp Ther. 1988;244:195-205.
93.
CheskinLJChamiTNJohnsonREJaffeJH. Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Drug Alcohol Depend. 1995;39:151-154.
94.
BüchlerMWSeilerCMMonsonJR. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther. 2008;28:312-325.
95.
LudwigKEnkerWEDelaneyCP. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg. 2008;143:1098-1105.
96.
DelaneyCPWolffBGViscusiER. Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies. Ann Surg. 2007;245:355-363.
97.
ThomasJKarverSCooneyGA. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358:2332-2343.
Progenics Pharmaceuticals, Inc. Wyeth Pharmaceuticals, Inc. Wyeth and Progenics announce preliminary clinical trial results for Relistor oral and intravenous formulations [press release]; 2008.
101.
Entereg [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008.
102.
BeckerGBlumHE. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet. 2009;373:1198-1206.
103.
PaulsonDMKennedyDTDonovickRA. Alvimopan: An oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction. A 21-day treatment randomized clinical trial. J Pain. 2005;6:184-192.
104.
GlaxoSmithKline and Adolor Corporation. GlaxoSmithKline and Adolor report top line results from phase 3 studies of Alvimopan [press release]; 2006.
105.
GlaxoSmithKline and Adolor Corporation. GSK and Adolor announce preliminary results from Phase 3 Safety study of Alvimopan (Entereg/Entrareg) [press release]; 2007.
LawNMBharuchaAEUndaleAS. Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans. Am J Physiol Gastrointest Liver Physiol. 2001;281:G1228-G1237.
109.
De GiorgioRKnowlesCH. Acute colonic pseudo-obstruction. Br J Surg. 2009;96:229-239.
SaundersMD. Acute colonic pseudo-obstruction. Best Pract Res Clin Gastroenterol. 2007;21:671-687.
112.
PonecRJSaundersMDKimmeyMB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999;341:137-141.
113.
ParanHSilverbergDMayoAShwartzINeufeldDFreundU. Treatment of acute colonic pseudo-obstruction with neostigmine. J Am Coll Surg. 2000;190:315-318.
114.
TrevisaniGTHymanNHChurchJM. Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction. Dis Colon Rectum. 2000;43:599-603.
115.
AlthausenPLGuptaMCBensonDRJonesDA. The use of neostigmine to treat postoperative ileus in orthopedic spinal patients. J Spinal Disord. 2001;14:541-545.
116.
AbeytaBJAlbrechtRMSchermerCR. Retrospective study of neostigmine for the treatment of acute colonic pseudo-obstruction. Am Surg. 2001;67:265-268.
117.
MehtaRJohnANairP. Factors predicting successful outcome following neostigmine therapy in acute colonic pseudo-obstruction: a prospective study. J Gastroenterol Hepatol. 2006;21:459-461.
118.
LoftusCGHarewoodGCBaronTH. Assessment of predictors of response to neostigmine for acute colonic pseudo-obstruction. Am J Gastroenterol. 2002;97:3118-3122.
119.
van der SpoelJIOudemans-van StraatenHMStoutenbeekCPBosmanRJZandstraDF. Neostigmine resolves critical illness-related colonic ileus in intensive care patients with multiple organ failure. A prospective, double-blind, placebo-controlled trial. Intensive Care Med. 2001;27:822-827.
120.
Foxx-OrensteinAEMcNallyMAOdunsiST. Update on constipation: one treatment does not fit all. Cleve Clin J Med. 2008;75:813-824.
121.
GhoshalUC. Review of pathogenesis and management of constipation. Trop Gastroenterol. 2007;28:91-95.
122.
FanLLGrahamLM. Radiological cases of the month. Lipoid pneumonia from mineral oil aspiration. Arch Pediatr Adolesc Med. 1994;148:205-206.
123.
BandlaHPDavisSHHopkinsNE. Lipoid pneumonia: a silent complication of mineral oil aspiration. Pediatrics. 1999;103:E19.
124.
ZanettiGMarchioriEGasparettoTDEscuissatoDLSoares SouzaAJr. Lipoid pneumonia in children following aspiration of mineral oil used in the treatment of constipation: high-resolution CT findings in 17 patients. Pediatr Radiol. 2007;37:1135-1139.
125.
MeltzerEGurandaLVassilenkoLKrupskyMSteinlaufSSidiY. Lipoid pneumonia: a preventable complication. Isr Med Assoc J. 2006;8:33-35.
126.
Van der SpoelJIOudemans-van StraatenHMKuiperMAvan RoonENZandstraDFvan der VoortPH. Laxation of critically ill patients with lactulose or polyethylene glycol: a two-center randomized, double-blind, placebo-controlled trial. Crit Care Med. 2007;35:2726-2731.
127.
PatanwalaAEAbarcaJHuckleberryYErstadBL. Pharmacologic management of constipation in the critically ill patient. Pharmacotherapy. 2006;26:896-902.
KellyTWJPatrickMRHillmanKM. Study of diarrhea in critically ill patients. Crit Care Med. 1983;11:7-9.
132.
BlissDZGuenterPASettleRG. Defining and reporting diarrhea in tube-fed patients, what a mess!Am J Clin Nutr. 1992;55:753-759.
133.
BaldiFBiancoMANardoneGPilottoAZamparoE. Focus on acute diarrhoeal disease. World J Gastroenterol. 2009;15:3341-3348.
134.
SabolVKCarlsonKK. Diarrhea: applying research to bedside practice. AACN Adv Crit Care. 2007;18:32-44.
135.
WeisenPvan GossumAPreiserJC. Diarrhoea in the critically ill. Curr Opin Crit Care. 2006;12:149-154.
136.
EdesTEWalkBEAustinJL. Diarrhea in tube-fed patients: Feeding formula not necessarily the cause. Am J Med. 1990;88:91-93.
137.
BartlettJG. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334-339.
138.
BartlettJG. Narrative review: The new epidemic of clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145:758-764.
139.
ImhoffAKarpaK. Is there a future for probiotics in preventing Clostridium difficile-associated disease and treatment of recurrent epidodes?Nutr Clin Pract. 2009;24:15-32.
140.
DialSAlrasadiKManoukianCHuangAMenziesD. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton-pump inhibitors: cohort and case-control studies. CMAJ. 2004;171:33-38.
141.
DialSDelaneyJABarkunANSuissaS. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294:2989-2995.
142.
CadleRMMansouriMDLoganNKudvaDRMusherDM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health-Syst Pharm. 2007;64:2359-2363.
143.
BeaulieuMWilliamsonDPichetteGLachaineJ. Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol. 2007;28:1305-1307.
144.
ModenaSBearellyDSwartzKFriedenbergFK. Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study. Infect Control Hosp Epidemiol. 2005;26:685-690.
145.
VestaKSWellsPGGentryCAStipekWJ. Specific risk factors for Clostridium difficile-associated diarrhea: A prospective, multicenter, case control evaluation. Am J Infect Control. 2005;33:469-472.
146.
BlissDZJohnsonSSavikKClabotsCWillardKGerdingDN. Acquisition of Clostridium difficile and clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med. 1998;129:1012-1019.
147.
ZilberbergMDShorrAFMicekSTDohertyJAKollefMH. Clostridium difficile-associated disease and mortality among the elderly critically ill. Crit Care Med. 2009;37:2583-2589.
148.
MusherDMAslamS. Treatment of clostridium difficile colitis in the critical care setting. Crit Care Clin. 2008;24:279-291.
149.
CunhaBA. Nosocomial diarrhea. Crit Care Clin. 1998;14:329-338.
150.
Van der SpoelJISchultzMJvan der VoortPHJde JongeE. Influence of severity of illness, medication and selective decontamination on defecation. Intensive Care Med. 2006;32:875-880.
151.
FerrieSEastV. Managing diarrhoea in intensive care. Aust Crit Care. 2007;20:7-13.
152.
DickersonRNMelnikG. Osmolality of oral drug solutions and suspensions. Am J Hosp Pharm. 1988;45:832-834.
153.
JohnstonKRGovelLAAndritzMH. Gastrointestinal effects of sorbitol as an additive in liquid medications. Am J Med. 1994;97:185-191.
LutomskiDMGoraMLWrightSMMartinJE. Sorbitol content of selected oral liquids. Ann Pharmacother. 1993;27:269-274.
156.
HyamsJS. Sorbitol intolerance: an unappreciated cause of functional gastrointestinal complaints. Gastroenterology. 1983;84:30-33.
157.
ScarlettY. Medical management of fecal incontinence. Gastroenterology. 2004;126(1 suppl 1):S55-S63.
158.
EricssonCDEvansDGDuPontHLEvansDJJrPickeringLK. Bismuth subsalicylate inhibits activity of crude toxins of Escherichia coli and Vibrio cholerae. J Infect Dis. 1977;136:693-696.
159.
BurkeVGraceyM. Effects of salicylate on intestinal absorption: in vitro and in vivo studies with enterotoxigenic micro-organisms. Can J Comp Med. 1978;42:260-268.
160.
GylesCLZiglerM. The effect of adsorbant and anti-inflammatory drugs on secretion in ligated segments of pig intestine infected with Escherichia coli. Can J Comp Med. 1978;42:260-268.
161.
Soriano-BrücherHAvendañoPO’RyanM. Bismuth subsalicylate in the treatment of acute diarrhea in children: a clinical study. Pediatrics. 1991;87:18-27.
162.
PickeringLKFeldmanSEricssonCDClearyTG. Absorption of salicylate and bismuth from a bismuth subsalicylate-containing compound (Pepto-Bismol). J Pediatr. 1981;99:654-656.
163.
DuPontHLFlores SanchezJEricssonCD. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. Am J Med. 1990;88:15S-19S.
164.
WeissK. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int J Antimicrob Agents. 2009;33:4-7.
SteevensECLipscombAFPooleGVSacksGS. Comparison of continuous vs intermittent nasogastric enteral feeding in trauma patients: Perceptions and practice. Nutr Clin Pract. 2002;17:118-122.
167.
ShangEGeigerNSturmJWPostS. Pump-assisted versus gravity-controlled enteral nutrition in long-term percutaneous endoscopic gastrostomy patients: a prospective controlled trial. JPEN J Parenter Enteral Nutr. 2003;27:216-219.
168.
LeeJSAuteungTW. A comparison of two feeding methods in the alleviation of diarrhoea in older tube-fed patients: a randomized controlled trial. Age Ageing. 2003;32:388-393.
169.
ParrishCR. Enteral feeding: the art and the science. Nutr Clin Pract. 2003;18:76-85.
SchneiderSMGirard-PipauFAntyR. Effects of total enteral nutrition supplemented with a multi-fibre mix on faecal short-chain fatty acids and microbiota. Clin Nutr. 2006;25:82-90.
172.
MarianMCarlsonSJ. Enteral formulations. In: MerrittR, ed. The A.S.P.E.N. Nutrition Support Practice Manual. 2nd ed.Silver Spring, MD: The American Society for Parenteral and Enteral Nutrition; 2005:63-75.
173.
ToddPABenfieldPGoaKL. Guar gum: A review of its pharmacological properties, and use as a dietary adjunct in hypercholesterolaemia. Drugs. 1990;39:917-928.
174.
EliaMEngferMBGreenCJSiklDBA. Systematic review and meta-analysis: the clinical and physiological effects of fibre-containing enteral formulae. Aliment Pharmacol Ther. 2008;27:120-145.
175.
SpapenHDiltoerMvan MalderenCOpdenackerGSuysEHuyghensL. Soluble fiber reduces the incidence of diarrhea in septic patients receiving total enteral nutrition: a prospective, double-blind, randomized, and controlled trial. Clin Nutr. 2001;20:301-305.
176.
RushdiTAPichardCKhaterYH. Control of diarrhea by fiber-enriched diet in ICU patients on enteral nutrition: a prospective randomized controlled trial. Clin Nutr. 2004;23:1344-1352.
177.
YangGWuXTZhouYWangYL. Application of dietary fiber in clinical enteral nutrition: a meta-analysis of randomized controlled trials. World J Gastroenterol. 2005;11:3935-3938.
178.
RohdeCLBartoliniVJonesN. The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea. Nutr Clin Pract. 2009;24:33-40.
SalminenMKRautelinJTynkkynenS. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004;38:62-69.
CassoneMSerraPMondelloF. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol. 2003;41:5340-5343.
184.
BesselinkMGHvan SantvoortHCBuskensE. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:651-659.
185.
ManzanaresWHardyG. The role of prebiotics and synbiotics in critically ill patients. Curr Opin Clin Nutr Metab Care. 2008;11:782-789.
SpainDAMcClaveSASextonLK. Infusion protocol improves delivery of enteral tube feeding in the critical care unit. JPEN J Parenter Enteral Nutr. 1999;23:288-292.
188.
DoigGSSimpsonFFinferS; Nutrition Guidelines Investigators of the ANZICS Clinical Trials Group. Effect of evidence-based feeding guidelines on mortality of critically ill adults: a cluster randomized controlled trial. JAMA. 2008;300:2731-2741.
HeylandDKDhaliwalRDayAJainMDroverJ. Validation of the Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients: results of a prospective observational study. Crit Care Med. 2004;32:2260-2266.
191.
MillerCAGrossmanSHindleyEMacGarvieDMadillJ. Are enterally fed ICU patients meeting clinical practice guidelines?Nutr Clin Pract. 2008;23:642-650.
